Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Henkel

This article was originally published in The Rose Sheet

Executive Summary

In preliminary first quarter results, Dusseldorf, Germany company announces that the cosmetics and toiletries business achieved organic sales growth of 3 percent to about $939 million, and operating profit advanced 3.4 percent to $117.4 million. A 19 percent decrease in organic sales of the adhesives technology business dragged total organic sales down 7 percent to $4.24 billion, though net sales increased 3 percent. Operating profit declined 32.8 percent to $280.4 million. Though the firm says it is dissatisfied with its results, it has the strength to emerge from the difficult economic environment and believes 2009 will be a "major step towards achieving our long-term targets.

You may also be interested in...



Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.

Sandoz Looks To Biosimilars As It Reprioritizes In The US

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

UsernamePublicRestriction

Register

RS016096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel